BFS
RARE icon

Bare Financial Services’s Ultragenyx Pharmaceutical RARE Stock Holding History

Bare Financial Services’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$668 Buy
+20
New +$497 ﹤0.01% 1546
2026
Q1 		– Sell
-45
Closed -$1.03K – 1856
2025
Q4 		$1.03K Buy
45
+24
+114% +$789 ﹤0.01% 1122
2025
Q3 		$632 Sell
21
-10
-32% -$300 ﹤0.01% 1173
2025
Q2 		$1.13K Buy
+31
New +$1.12K ﹤0.01% 883

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Bare Financial Services's RARE Position: Q2 2026 in Review

Bare Financial Services opened a new position in Ultragenyx Pharmaceutical (RARE) in Q2 2026: 20 shares worth $668. The stake represents ﹤0.01% of the portfolio and ranks #1546 among its holdings. This is a return to the name: Bare Financial Services previously reported a position in RARE as recently as Q4 2025.

Bare Financial Services first reported a position in RARE in Q2 2025 and has held it in 4 quarters since. The position peaked at $1.13K in Q2 2025. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Bare Financial Services held 20 shares of Ultragenyx Pharmaceutical worth $668 as of Q2 2026.
  • Ultragenyx Pharmaceutical was a new Bare Financial Services position in Q2 2026.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Bare Financial Services's portfolio in Q2 2026, its #1546 holding.
  • Bare Financial Services first reported a position in Ultragenyx Pharmaceutical in Q2 2025 and has held it in 4 quarters since.
  • Bare Financial Services's Ultragenyx Pharmaceutical position peaked at $1.13K in Q2 2025.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Bare Financial Services's 13F filing for Q2 2026, filed 27 Jul 2026.